Insights into efficacy and safety of dapagliflozin treatment for the management in older adults with type 2 diabetes: a systematic review and meta-analysis

被引：2

作者：

Jiang, Lili ^{[1
]}

Jia, Yanyan ^{[1
]}

Wang, Xiaoyu ^{[1
]}

Wang, Zhe ^{[1
]}

Lv, Xin ^{[1
]}

Jia, Yaqin ^{[1
]}

Feng, Yuyi ^{[1
]}

Yin, Hang ^{[1
]}

Yan, Mingrui ^{[1
]}

Fan, Xiaoyu ^{[1
]}

Liu, Yong ^{[1
,2
]}

机构：

[1] Dalian Univ Technol, Sch Life & Pharmaceut Sci, Panjin, Liaoning, Peoples R China

[2] Dalian Univ Technol, Sch Life & Pharmaceut Sci, 2 Dagong Rd, Panjin 124221, Liaoning, Peoples R China

来源：

EXPERT OPINION ON DRUG SAFETY | 2023年 / 22卷 / 05期

关键词：

Dapagliflozin; older adults; type 2 diabetes mellitus; efficacy; safety; DOUBLE-BLIND; INHIBITORS; MELLITUS; MULTICENTER; NETWORK; 24-WEEK; RISK;

D O I：

10.1080/14740338.2023.2166485

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

BackgroundThis study aimed to evaluate the efficacy and safety of dapagliflozin as a monotherapy glucose-lowering drug treatment for older adults with diabetes.Research Design & MethodsRandomized controlled trial reports were retrieved from PubMed, Embase Cochrane Library, and Web of Science from database inception to 8 May 2021. Publication bias and heterogeneity were assessed using the Cochrane risk-of-bias tool and the Cochrane Q statistic, respectively.ResultsCompared with placebo, dapagliflozin as a monotherapy glucose-lowering drug did improve the control of glycosylated hemoglobin and fasting plasma glucose levels in older adults. Our analysis also confirmed that the body weight of older adults was well controlled under treatment of dapagliflozin as a monotherapy glucose-lowering drug. Patients in older adults with diabetes took a higher risk of genital infection and renal impairment or failure after treatment of dapagliflozin. In addition, treatment with dapagliflozin reduced the risk of hypoglycemia, and did not reveal increased risk of urinary tract infection and developing fractures compared to placebo in older adults.ConclusionsDapagliflozin as a monotherapy glucose-lowering drug appeared to be an effective treatment for older adults with diabetes, although it might increase risk of genital infection and renal impairment or failure.

引用

页码：407 / 416

页数：10

共 44 条

[1] Disability and quality of life in elderly people with diabetes [J].

Bourdel-Marchasson, I. ;

Helmer, C. ;

Fagot-Campagna, A. ;

Dehail, P. ;

Joseph, P. A. .

DIABETES & METABOLISM, 2007, 33 :S66-S74

[2] Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study [J].

Cahn, Avivit ;

Mosenzon, Ofri ;

Wiviott, Stephen D. ;

Rozenberg, Aliza ;

Yanuv, Ilan ;

Goodrich, Erica L. ;

Murphy, Sabina A. ;

Bhatt, Deepak L. ;

Leiter, Lawrence A. ;

McGuire, Darren K. ;

Wilding, John P. H. ;

Gause-Nilsson, Ingrid A. M. ;

Fredriksson, Martin ;

Johansson, Peter A. ;

Langkilde, Anna Maria ;

Sabatine, Marc S. ;

Raz, Itamar .

DIABETES CARE, 2020, 43 (02) :468-475

[3] Combination Therapy With Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Older Patients With Type 2 Diabetes: A Real-World Evidence Study [J].

Carretero Gomez, Juana ;

Arevalo Lorido, Jose Carlos ;

Gomez Huelgas, Ricardo ;

Garcia de Lucas, Dolores ;

Mateos Polo, Lourdes ;

Varela Aguilar, Jose Manuel ;

Segui Ripoll, Jose Miguel ;

Ena, Javier .

CANADIAN JOURNAL OF DIABETES, 2019, 43 (03) :186-192

[4] Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension [J].

Cefalu, William T. ;

Leiter, Lawrence A. ;

de Bruin, Tjerk W. A. ;

Gause-Nilsson, Ingrid ;

Sugg, Jennifer ;

Parikh, Shamik J. .

DIABETES CARE, 2015, 38 (07) :1218-1227

[5] Epidemiology of Diabetes and Diabetes Complications in the Elderly: An Emerging Public Health Burden [J].

Corriere, Mark ;

Rooparinesingh, Nira ;

Kalyani, Rita Rastogi .

CURRENT DIABETES REPORTS, 2013, 13 (06) :805-813

[6] Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus A meta-analysis of randomized controlled trials [J].

Feng, Miao ;

Lv, Haihong ;

Xu, Xia ;

Wang, Jue ;

Lyu, Wenyi ;

Fu, Songbo .

MEDICINE, 2019, 98 (30)

[7] Insulin action and age [J].

Ferrannini, E ;

Vichi, S ;

BeckNielsen, H ;

Laakso, M ;

Paolisso, G ;

Smith, U .

DIABETES, 1996, 45 (07) :947-953

[8] Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study [J].

Fioretto, Paola ;

Del Prato, Stefano ;

Buse, John B. ;

Goldenberg, Ronald ;

Giorgino, Francesco ;

Reyner, Daniel ;

Langkilde, Anna Maria ;

Sjostrom, C. David ;

Sartipy, Peter .

DIABETES OBESITY & METABOLISM, 2018, 20 (11) :2532-2540

[9] Efficacy of SGLT-2 inhibitors in older adults with diabetes: Systematic review with meta-analysis of cardiovascular outcome trials [J].

Giugliano, Dario ;

Longo, Miriam ;

Maiorino, Maria Ida ;

Bellastella, Giuseppe ;

Chiodini, Paolo ;

Solerte, Sebastiano Bruno ;

Esposito, Katherine .

DIABETES RESEARCH AND CLINICAL PRACTICE, 2020, 162

[10] The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis [J].

Guo, Man ;

Gu, Junling ;

Teng, Fangyuan ;

Chen, Jiao ;

Ma, Xiumei ;

Chen, Qing ;

Pu, Yueli ;

Jiang, Zongzhe ;

Long, Yang ;

Xu, Yong .

ENDOCRINE, 2020, 67 (02) :294-304

← 1 2 3 4 5 →